



<http://dx.doi.org/10.1080/10717544.2018.1468888>



Nano-engineered microcapsules boost the treatment of persistent pain

Journal:	<i>Drug Delivery</i>
Manuscript ID	UDRD-2017-0496.R1
Manuscript Type:	Original Paper
Date Submitted by the Author:	16-Jan-2018
Complete List of Authors:	Kopach, Olga; University College London, UCL Institute of Neurology Zheng, Kaiyu; University College London, UCL Institute of Neurology Dong, Luo; Queen Mary University of London, School of Engineering and Materials Science Sapelkin, Andrei; Queen Mary University of London, School of Engineering and Materials Science Voitenko, Nana; Institut Fiziologii imeni O O Bogomolca Nacional'na akademija nauk Ukraini Sukhorukov, Gleb; Queen Mary University of London, School of Engineering and Materials Science Rusakov, Dmitri; University College London, UCL Institute of Neurology
Keywords:	biodegradable microcapsules, persistent pain, layer-by-layer, QX-314, inflammatory pain

SCHOLARONE™
Manuscripts

Nano-engineered microcapsules boost the treatment of persistent pain

Olga Kopach¹, Kayiu Zheng¹, Luo Dong², Andrei Sapelkin³, Nana Voitenko⁴, Gleb B. Sukhorukov², Dmitri A. Rusakov¹

¹Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, University College London, Queen Square, London WC1N 3BG, U.K.

²School of Engineering and Materials Science, Queen Mary University of London, Mile End Road, London E1 4NS, U.K.

³Centre for Condensed Matter and Materials Physics, Queen Mary University of London, Mile End Road, London E1 4NS, U.K.

⁴Department of Sensory Signaling, Bogomoletz Institute of Physiology, 4 Bogomoletz Street, Kyiv 01024, Ukraine

Correspondence: d.rusakov@ucl.ac.uk, o.kopach@ucl.ac.uk, or g.sukhorukov@qmul.ac.uk

Abbreviated title: Drug microencapsulation for pain treatment

Word count: 7995

ABSTRACT

Persistent pain remains a major health issue: the common treatments relying on either repeated local injections or systemic drug administration are prone to concomitant side-effects. It is thought that an alternative could be a multifunctional cargo system to deliver medicine to a target site and release it over a prolonged time window. We nano-engineered microcapsules equipped with adjustable cargo release properties and encapsulated the sodium channel blocker QX-314 using the layer-by-layer (LbL) technology. First, we employed single-cell electrophysiology to establish *in vitro* that microcapsule application can dampen neuronal excitability in a controlled fashion. Secondly, we used two-photon excitation imaging to monitor and adjust long-lasting release of encapsulated cargo in target tissue *in situ*. Finally, we explored an established peripheral inflammation model in rodents to find that a single local injection of QX-314-containing microcapsules could provide a robust pain relief lasting for over a week. This was accompanied by a recovery of the locomotive deficit and the amelioration of anxiety in animals with persistent inflammation. Post-hoc immunohistology confirmed biodegradation of microcapsules over a period of several weeks. The overall remedial effect lasted 10-20 times longer than that of a single focal drug injection. It depended on the QX-314 encapsulation levels, involved TRPV1-channel-dependent cell permeability of QX-314, and showed no detectable side-effects. Our data suggest that nano-engineered encapsulation provides local drug delivery suitable for prolonged pain relief, which could be highly advantageous compared to existing treatments.

Keywords: biodegradable microcapsules, persistent pain, Na⁺ channels, drug diffusion, neuronal excitability, pain relief, locomotive deficit and anxiety.

INTRODUCTION

Persistent or chronic pain remains largely resistant to treatment. In practice, the analgesics of choice have been opiates and Na⁺ channel blockers, such as lidocaine. However, their use has been restricted by side-effects, such as sedation for opiates and cardiotoxicity for lidocaine and its derivatives. These factors curtail the amount administered, mainly due to the risk of a rapid systemic escape from the target site or from a drug depot. Furthermore, existing methods of focal drug application have principal limitations: singular injections provide poor control over the application kinetics whereas chronic injecting devices are invasive, costly, and are prone to the infection risk.

Over the years, various medicine cargo systems have been explored and tested for their capability of targeted drug delivery (Sukhorukov *et al.*, 2005, Tanbour *et al.*, 2016), including pain treatment. Some notable attempts utilized hydrogels involving steroid treatment (Liu *et al.*, 2016), photo-triggered liposomes carrying Na⁺ channel blocker tetrodotoxin (Rwei *et al.*, 2015, Zhan *et al.*, 2016), or immunoliposomes for opioid delivery (Hua and Cabot, 2013). A major challenge has been, however, to incorporate multiple functionalities into a single entity, which would deliver medicine to the target site and release it over a relatively long period, in a controllable fashion (Sukhorukov *et al.*, 2005, Sukhorukov and Mohwald, 2007, Stuart *et al.*, 2010). One promising direction has been biodegradable polyelectrolyte-based microcapsule systems constructed with the layer-by-layer (LbL) method (Decher, 1997, Stuart *et al.*, 2010). Such systems could incorporate different polyelectrolytes and charged nanoparticles in a single LbL capsule combining several functionalities. A wide variety of substances have successfully been tried as cargo for encapsulation (De Cock *et al.*, 2010).

In brief, the LbL microcapsules could be made controllably to a size of 0.3 μm or larger, with the outer layers providing their functional features, such as varied permeability (cargo release rate) or sensitivity to the external stimuli (pH, temperature, osmolarity, light, etc.) (Munoz Javier *et al.*, 2008; Antipina and Sukhorukov, 2011a; Delcea *et al.*, 2011a; Pavlov *et al.*, 2011; Pavlov *et al.*, 2013; Gao *et al.*, 2016b). The microcapsules are routinely made of biodegradable components and show no toxicity or appreciable

1
2
3 inflammation or apoptotic effects when injected in tissue or internalized by cultured cells
4 (Pavlov et al., 2011).
5

6
7 Among the analgesics used for local pain treatment there has been a growing interest in
8 the Na⁺ channel blocker QX-314, which appears to produce relatively long-lasting
9 analgesic effects, at relatively higher potency, in animal models (Lim et al., 2007b;
10 Roberson et al., 2011b; Zhao et al., 2014a). Whilst QX-314 is membrane-impermeable
11 and blocks Na⁺ channels from the cytoplasm side, studies *in situ* have established that it
12 enters nerve cells through the transient receptor potential (TRP) receptors TRPV1 and
13 TRPA1 (Binshtok et al., 2007a; Leffler et al., 2011a; Puopolo et al., 2013; Stueber et al.,
14 2016), which are strongly expressed in peripheral nociceptors (pain-signaling neurons),
15 but also through a TRP-independent mechanism (Brenneis et al., 2014b; Hofmann et
16 al., 2014a). These findings have prompted calls for further validation of this potentially
17 efficient analgesic (Roberson et al., 2011b; Stueber et al., 2016).
18
19
20
21
22
23
24
25

26 Notwithstanding the promise of LbL encapsulation technology, there have been no
27 systematic attempts to adapt it to the explorative studies of therapeutic intervention. We
28 therefore set out to test whether drug delivery via nano-engineered LbL microcapsules
29 has a therapeutic potential in the context of pain treatment. Here we encapsulate QX-
30 314 in biodegradable microcapsules made of poly-L-arginine and dextran sulphate,
31 adjust and test its release action *in vitro* and *in situ*, and document the effects of
32 encapsulated QX-314 (injected subcutaneously) in a persistent inflammatory pain model
33 in rodents *in vivo*.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

MATERIALS AND METHODS

Design and fabrication of microcapsules

Polymer-based multilayer microcapsules were fabricated in accord with the previously established LbL assembly technique (Sukhorukov and Mohwald, 2007, Stuart *et al.*, 2010). Quaternary lidocaine derivative QX-314 chloride, the membrane-impermeable blocker of voltage-gated Na⁺ channels, was encapsulated at variable amounts (4 to 10 pg *per* capsule). Briefly, CaCO₃ was used as sacrificial templates, and poly-L-arginine (PArg) was deposited as the first layer and incubated for 15 min, then washed three times; the oppositely charged dextran sulphate sodium salt (DXS) was assembled as the second layer with the same procedure. In order to encapsulate QX-314 into the capsule shells, two of the DXS layers were substituted by QX-314 during the assembly process. Polymer solutions and QX-314 solutions were prepared at 2 mg/ml. For fluorescent visualization one of the PArg layers was labelled with TRITC. After the assembly of eight layers, the CaCO₃ cores were removed with 0.2 M EDTA. The resulting microcapsule architecture was PArg/DXS/QX-314/DXS/QX-314/DS/PArg-TRITC/DXS. Empty microcapsules (no payload) were used as control. The concentration of capsules in suspension was determined by a hemocytometer (density range 1.1-2.2×10⁸ 1/ml). The QX-314 encapsulation rate was calculated by measuring the remaining QX-314 in supernatants. The suspension of microcapsules was stored at 4 °C. To assess the encapsulated cargo release rate, the microcapsules of a similar configuration were made, with one of the DXS layer substituted by Alexa Fluor 488 hydrazide (ThermoFisher Scientific).

Primary neuron cultures

Hippocampal neurons were isolated from the Sprague-Dawley rat pups (P0 to P2 day-old), in accordance with the European Commission Directive (86/609/EEC) and the United Kingdom Home Office (Scientific Procedures) Act (1986). Neurons were cultured in NeuroBasal A/B27-based medium on a rat astrocyte feeder layer at 37°C as described (Ermolyuk *et al.*, 2013). Cultured neurons were placed in a recording chamber mounted on the stage of an Olympus BX51WI upright microscope (Olympus,

1
2
3 Japan) equipped with a LUMPlanFI/IR 40×0.8 objective coupled to an infrared DIC
4 imaging system.
5
6
7
8

9 ***Electrophysiology***

10
11 Electrophysiological recordings were carried out using a Multipatch 700B amplifier
12 controlled by the pClamp 10.2 software package (Molecular Devices, USA). Recordings
13 were made in a bicarbonate-buffered solution (aCSF) containing (in mM) 126 NaCl, 3
14 KCl, 2 MgSO₄, 2 CaCl₂, 26 NaHCO₃, 1.25 NaH₂PO₄, 10 D-glucose saturated with 95%
15 O₂ and 5% CO₂ (pH 7.4; 300–310 mOsmol) at 31–33°C. The recording electrode
16 resistance was 2.5–5 MΩ when filled with the intracellular solution containing (in mM)
17 126 K-gluconate, 10 HEPES, 4 KCl, 4 MgCl₂, 2 BAPTA, 4 Mg-ATP, 0.4 GTP-Na (pH 7.2
18 with KOH, osmolarity ~290 mOsmol). For the intracellular delivery of microcapsules, the
19 glass electrode tip was back-filled with a suspension of microcapsules supplemented to
20 the intracellular solution. The presence of microcapsules at the pipette tip was
21 confirmed by visualizing their TRITC (FITC) fluorescence (conjugated to the capsule
22 shell) prior to the breaking into whole-cell mode. Once in whole-cell, neurons were
23 monitored for changes in their intrinsic active and passive membrane properties using
24 fast sampling (20 kHz) every 1–3 min, until the baseline had stabilized (40–50 minutes).
25 The series of sub- and supra-threshold rectangular current pulses (500- to 1000-ms-
26 duration) of the gradually (stepwise) increased stimulus intensity were applied. The
27 steady-state input resistance (R_{input}) was estimated from the measured current-voltage
28 relationship at various time points during the experiment. The maximal firing frequency
29 and the corresponding (minimal) membrane voltage were monitored throughout.
30 Changes in the action potentials (AP) shape were analyzed using the first AP spike
31 responding to a slow-ramp input current (ramp slope 480 pA/s).
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 ***Acute skin tissue preparation***

51
52 Peripheral tissue was taken from the plantar surface of the hind paw of Sprague-Dawley
53 rats (21 to 25-day-old) following animal sacrifice. Tissue sections (300–350 μm
54
55
56
57
58
59
60

1
2
3 thickness) consisting of skin layers and the tissue beneath were cut using a tissue
4 chopper (McIlwain Model TC752, Mickle Laboratory Engineering Co.). Acute slices were
5 placed in the recording chamber mounted on the stage of an Olympus upright
6 microscope (Olympus, Japan) and maintained in HEPES-based physiological buffer.
7
8
9

10 11 12 **Imaging of encapsulated drug release**

13
14
15 Microcapsules containing Alexa Fluor-488 (similar molecular weight to QX-314) were
16 delivered into acute skin tissue *in situ* with a glass pipette positioned between epidermal
17 and dermal layers. One-photon (confocal) or two-photon (2P) excitation fluorescent
18 imaging was carried out with either a Radiance 2000 (Zeiss-Bio-Rad) or a Femto2D
19 (Femtonics, Budapest) system optically linked to a Ti:Sapphire Mai-Tai femtosecond
20 pulse laser (SpectraPhysics-Newport), with various digital zooms, appropriate emission
21 filters, and excitation at $\lambda_x^{2P} = 800$ nm, as detailed earlier (Zheng *et al.*, 2015, Mishra *et*
22 *al.*, 2016). The z-stacks of fluorescent images were collected every 5-10 min using
23 512×512 pixel frames (typically 30–50 optical sections in 1- μ m z-steps) for time-lapse
24 monitoring of Alexa Fluor 488 fluorescence upon microcapsule injection (overall, 5 to 8
25 hours *in situ*). To provide a direct *in situ* comparison of the diffusion escape rates
26 between non-capsulated and encapsulated Alexa Fluor 488, the former was injected
27 between epidermal and dermal layers with another glass pipette near the
28 microcapsules. In a separate set of experiments, microcapsules carrying Alexa Fluor
29 488 were placed in glycerol (99%) and monitored using a fast-scanning confocal
30 fluorescence microscope (750 to 1000 lines/sec) in a photon-count mode, as described.
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **Animals in behavioral studies**

46
47 The animals used for behavioral studies were 2.5- to 3-month-old male Wistar rats. All
48 animal procedures were approved by the local Animal Ethics Committee (Bogomoletz
49 Institute of Physiology, Kyiv, Ukraine): there were performed in full compliance with the
50 ethical guidelines of the International Association for the Study of Pain and the United
51 States Public Health Service's Policy on Humane Care and Use of Laboratory Animals,
52
53
54
55
56
57
58
59
60

1
2
3 as detailed in our previous works (Park *et al.*, 2009b, Kopach *et al.*, 2012, Kopach *et al.*,
4 2016). Animal procedures were fully compliant with the European Commission Directive
5 (86/609/ EEC) and the United Kingdom Home Office (Scientific Procedures) Act (1986).
6
7
8
9

10 11 ***Experimental design of pain models in vivo***

12
13 To produce unilateral peripheral inflammation and persistent nociceptive
14 hypersensitivity, 50–100 µl of complete Freund's adjuvant (CFA, Sigma Chemicals, St.
15 Louis, USA) suspended in an oil-saline (1:1) emulsion was injected subcutaneously into
16 the plantar side of one hind paw of rats (Kopach *et al.*, 2013, Kopach *et al.*, 2015,
17 Kopach *et al.*, 2016). Encapsulated QX-314 was injected as a post-treatment of
18 nociceptive hypersensitivity (after induction of the CFA-induced peripheral
19 inflammation). Different groups of animals received a single intraplantar injection of
20 microcapsules (carrying QX-314 at various concentrations, or empty capsules) into the
21 inflamed tissue of the hind paw, in a total volume of 50 µl (diluted in saline) at 1 d post-
22 CFA, the time point indicating inflammatory pain maintenance (Kopach *et al.*, 2013,
23 Kopach *et al.*, 2016). A control group of the CFA-inflamed animals received a similar
24 injection of non-capsulated QX-314 or 2% lidocaine. In a separate set of experiments,
25 groups of non-inflamed animals (no CFA) received encapsulated QX-314 or empty
26 microcapsules. To produce unilateral acute peripheral hypersensitivity of neurogenic
27 origin, 50 µl of capsaicin (1.5 µg/µl, Sigma Chemicals) was injected intradermally into
28 the plantar side of one hind paw.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 ***Pain assessment***

45
46 The peripheral thermal pain threshold was measured using the Hargreaves technique,
47 as we described previously (Kopach *et al.*, 2012, Kopach *et al.*, 2016). Briefly, after an
48 animal was habituated to a Plexiglas chamber (Biological Research Apparatus, Ugo
49 Basile, Italy), an infrared heat stimulus was applied to the middle of the plantar surface
50 of hind paw. The heat beam was automatically turned off when the animal lifted its paw.
51 The time between the stimulus onset and the paw withdrawal was automatically
52
53
54
55
56
57
58
59
60

1
2
3 recorded: it represented the latency of nociceptive response (thermal pain threshold).
4 Measurements were repeated 3-5 times for each hind paw, the values were averaged.
5
6
7
8

9 ***Open-field test for animal' explorative behavior and anxiety***

10
11 To assess the sensorimotor function and animal locomotive behavior, an open-field test
12 (open-field arena) was used as detailed previously (Kopach *et al.*, 2016). In brief,
13 animals were placed in an open-field arena (a 75×75×40 cm wooden box with a digital
14 camera attached above) and allowed to move freely over a predefined time period (10
15 min). Recordings were analyzed with MATLAB software using in-house scripts. The
16 following parameters were monitored and recorded to assess locomotion: the total
17 distance travelled by an animal, the maximal speed, and the acceleration. The anxiety
18 level was assessed by computing the ratio between the fractions of time spent in the
19 arena center *versus* corners.
20
21
22
23
24
25
26
27
28
29

30 ***Immunohistology***

31
32 The localization of microcapsules injected *in vivo* was examined with post-hoc
33 immunohistology of the glabrous skin samples collected from the hind paw at different
34 time points post-injection. The dissected glabrous skin tissue (~1 cm) was fixed in 3%
35 PFA (1-2 days at 4°C). After fixation, samples were replaced into PBS containing 0.02%
36 sodium azide and underwent a cryo-protection treatment (10% sucrose for 2 h, then
37 20% - for 2 h, followed by 30% for overnight). Tissue was mounted in OCT and stored
38 at -80°C until processed for cryo-sectioning. The transverse tissue sections (30-60 µm
39 thick) were cut and collected as an ordered series. Floating tissue sections were rinsed
40 with PBS at least 3 times/5' each section and blocked with 1% BSA, 5% Donkey serum
41 in 0.2% Triton X-100 PBS for 4 hours. The primary antibodies were mouse anti-PGP9.5,
42 neuron cytoplasmic protein 9.5 (1:500; Merck Millipore U.K.). After incubation with
43 primary antibodies (2 days at 4°C), tissue sections were incubated with the secondary
44 antibodies (overnight at 4°C). Secondary antibodies were Alexa Fluor 488 from the
45 same host (1:200 or 1:400; Invitrogen). The following day sections were washed,
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 unrolled and mounted on glass slides using Vectashield H-1400 (Vector). Tissue
4 sections were scanned for both PGP9.5-positive structures and microcapsules using a
5 Radiance 2000 imaging system (Zeiss-Bio-Rad) or Femto2D (Femtonics) imaging
6 system using various digital zooms.
7
8
9

10 11 12 **Microcapsule biodegradability assay**

13
14
15 Tissue samples were collected at various time points post-injection (at 1, 5, and 10
16 weeks), fixed and processed for immunohistology (see above). Special care was taken
17 to make sure that the microcapsule injection parameters (microcapsule concentration in
18 suspension, pressure pulse, etc.) were uniform across the tested samples. To gauge the
19 spatial distribution of microcapsules across the peripheral tissue, we scanned the entire
20 tissue volume (transverse tissue sections cut and collected in a serial order) containing
21 all detectable capsules in a z-stack of individual focal x-y planes (3- μm z-step, total
22 scanned volume of $\sim 370 \mu\text{m}^3$) using a Femto2D (Femtonics) imaging system. The
23 fluorescence distributed in the z direction thus reported the amount of fluorescently
24 labelled capsules in the tissue volume.
25
26
27
28
29
30
31
32
33
34

35 **Statistics**

36
37 Unless indicated otherwise, summary data are presented as mean \pm SEM (standard
38 error of the mean) with n referring to the number of cells (in vitro experiments) or
39 animals (in vivo experiments) in the group. Student's t-test (two-tailed unpaired) was
40 used to determine statistical difference between experimental groups. The statistical
41 difference between groups of experimental animals was analyzed by one-way or two-
42 way analysis of variance (ANOVA) followed by Bonferroni *post hoc* test or Fisher test
43 where appropriate. A p value of less than 0.05 was considered as statistically significant
44 for either test.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

Encapsulated QX-314 can gradually suppress neuronal excitability *in vitro*

We fabricated polymeric LbL microcapsules and encapsulated the membrane-impermeable Na⁺ channels blocker QX-314 within the penultimate shell layer (4-10 pg *per* capsule; Figure 1A). The latter was to enable controllable shell permeability for the encapsulated compound. After initial trials, the capsule shell composition was adjusted to provide a cargo release rate of 4-5% *per* hour (decay constant ~20 h), which was gauged by monitoring the escape of encapsulated fluorescent dye (Alexa Fluor 488, a similar molecular weight to QX-314, Figure 1B).

To examine how the encapsulated QX-314 suppresses neuronal excitability, we delivered the microcapsules inside individual hippocampal neurons (primary culture) using a patch pipette in whole-cell configuration (Figure 1C). Thus, we monitored cell excitability in real time starting shortly upon microcapsule injection, and compared test groups with control (i.e., cells injected with empty microcapsules, or no capsules, Figure 1D-F). We found a gradual suppression of neuronal excitability, which progressed within 15–20 min after injecting encapsulated QX-314, leading to a sharp drop in the maximum firing rate ($n = 18$ cells, $p < 0.01$ compared with either empty microcapsules, $n = 12$, or no capsules, $n = 17$; Figure 1D). In parallel, encapsulated QX reduced the spike amplitude and the spike overshoot (amplitude above 0 mV; $n = 9$, $p < 0.001$ compared to that with no capsules, $n = 9$; Figure 1E-F).

We also confirmed that the cell input resistance remained stable over time and was not affected by the injection of empty capsules (Figure 2A-B). However, it gradually increased following injection of encapsulated QX-314, reflecting major ion channel blockade ($n = 14$, difference at $p < 0.05$ with the empty-microcapsule group, $n = 15$, or no-capsules group, $n = 14$; Figure 2C-D). In contrast, adding QX-314 directly to the intracellular solution (0.5 mM, and especially 5 mM, a commonly used concentration in whole-cell) suppressed spike generation almost immediately (Figure 2E-F). To replicate the slow progression of excitability blockade under encapsulated QX-314, intracellular concentration of non-encapsulated QX-314 had to be reduced at least 10^3 - 10^4 -fold (to ~500 nM; Figure 2F).

Microcapsule cargo release rate in skin tissue *in situ*

Because our ultimate goal was to test the pain-relieving effects of encapsulated QX-314, we first sought to establish the microcapsule cargo release properties in peripheral skin tissue *in situ*. To achieve this, we employed an acute skin tissue preparation from glabrous skin of the rat hind paw. Microcapsules with encapsulated Alexa Fluor 488 were delivered through a micropipette between epidermal and dermal layers and monitored using two-photon excitation (2PE) fluorescence microscopy (Figure 3A). Microcapsules showed a release rate constant of ~ 14 h (slow component), as evaluated by the time-lapse fluorescence emission monitoring of the encapsulated Alexa Fluor 488 *in situ* (Figure 3B). In contrast, Alexa Fluor 488 in a free solution injected nearby, directly into the tissue via a micropipette, was escaping at a rate of ~ 4.12 s (slow component; Figure 3C), i.e., $\sim 10^4$ times faster. In addition, we used photon counting (within ~ 1 μm focal plane), in line with procedures detailed earlier (Zheng *et al.*, 2015), to document a build-up of the diffuse fluorescence profile in the vicinity of individual microcapsules (Figure 3D). Within ~ 7 h post-injection *in situ*, this profile was consistent with the slow cargo diffusion escape from the microcapsules reported above (Figure 3E).

Encapsulated QX-314 provides long-lasting pain relief *in vivo*

To explore therapeutic potential of encapsulated QX-314, we turned to a well-established experimental paradigm of the CFA-induced unilateral persistent peripheral inflammation (Park *et al.*, 2009b, Kopach *et al.*, 2012, Kopach *et al.*, 2016). Following the intraplantar injection of CFA, animals displayed robust thermal hypersensitivity on the ipsilateral (but not contralateral) side, as evaluated by measuring the thermal pain threshold (see Methods). If left untreated, the hypersensitivity persisted at least over 11 days (Figure 4A), and a single focal subcutaneous injection of the common analgesic lidocaine had no long-lasting effect (Additional Figure 1).

1
2
3 The CFA-inflamed animals were quasi-randomly sampled to receive a single injection of
4 either encapsulated QX-314 or empty microcapsules into the sites of inflammation at
5 one day (1 d) post-CFA. Animals that received encapsulated QX-314 showed
6 substantially alleviated hypersensitivity, with a progressive recovery of the thermal pain
7 threshold back to the pre-inflammatory level by the next day (n = 6 rats, $p < 0.01$
8 compared with the CFA-inflamed group injected either empty microcapsules, n = 5, or
9 no capsules, n = 27; Figure 4A-B). Injecting empty capsules had no detectable effect (n
10 = 6 rats, Figure 4A and Additional Figure 1A) whereas a single focal injection of 100 mM
11 non-encapsulated QX-314 had only a brief and marginal relief of the thermal nociceptive
12 hypersensitivity (n = 5 rats, $p < 0.05$ compared with no treatment at 2 d post-CFA;
13 Figure 4A). We could routinely confirm with *post-hoc* immunohistology that
14 microcapsules were scattered within the epidermal-dermal area as targeted (Figure 4C).
15 Importantly, the therapeutic effect of encapsulated QX-314 remained significant for at
16 least 12 days ($p < 0.01$ between the CFA-inflamed group injected with 3 mM
17 encapsulated QX and that with empty microcapsules, over the experiment duration;
18 Figure 4A) and its time course depended on the concentration of encapsulated QX-314
19 (Figure 4B; $p < 0.001$ between the effects of 7.5 mM encapsulated QX-314, n = 7 rats,
20 and empty microcapsules, over 11 days post-CFA; but no difference between 0.01 mM
21 encapsulated QX-314, n = 5 and empty microcapsules over the 7-11 day period).
22 Separate experiments showed how the effect depended on the amount of QX-314
23 encapsulated *per* capsule (lasting over 12 days post-CFA for microcapsules containing
24 10 pg of encapsulated QX-314: n = 8 rats, $p < 0.01$ compared with empty
25 microcapsules, but up to 7 days for 4.5 pg of encapsulated QX-314, n = 5 rats; Figure
26 4D) and on the capsule size (Figure 4E; n = 6 rats, $p < 0.01$ for 2 μm microcapsules
27 containing 3 mM of encapsulated QX-314 and n = 5 rats, $p < 0.05$ for 1 μm
28 microcapsules compared with empty ones over the time of experiment).

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Control experiments confirmed that in healthy animals (no induced inflammation or
pain), neither empty microcapsules (Additional Figure 2A) nor encapsulated QX-314
(Additional Figure 2B) affected the peripheral thermal sensitivity, thus ruling out the
concomitant effects of microcapsules *per se*. There were no acute (within hours) or
delayed (days) effects on thermal sensitivity of the ipsilateral hind paw following

1
2
3 intraplantar injection of microcapsules as compared with the contralateral hind paw (no
4 capsules) or with the zero time-point (before injection; Additional Figure 2).
5
6
7

9 **Encapsulated QX-314 rescues locomotive deficit and animal anxiety produced by** 10 **peripheral inflammation** 11

12
13 We next examined whether the anti-nociceptive effect of encapsulated QX-314
14 influences the locomotor deficit and the heightened anxiety, which is often associated
15 with painful states (Kopach *et al.*, 2016). We thus implemented an open-field test, a
16 well-established assay for an integrative analysis of animal behavior, including anxiety
17 (Figure 5A). The group of animals with the CFA-induced inflammatory pain showed a
18 dramatic reduction in the travelled distance ($n = 5$ rats, $p < 0.01$ for each recorded post-
19 CFA time point compared with zero time-point; Figure 5B) that persisted for at least 10
20 days after CFA injection. An integrative analysis of animal behavior demonstrated that
21 encapsulated QX-314 progressively rescued the impaired locomotion in inflamed
22 animals within 2-4 days post-treatment ($n = 5$ rats, $p < 0.05$ compared with empty
23 microcapsules; Figure 5B), in a dose-dependent manner (Figure 5C). This was
24 consistent with the improved speed (Figure 5D) and acceleration (Additional Figure 3A).
25 The effect was paralleled by a decline in the anxiety-like behavior, which was monitored
26 as the proportion of time spent near the arena center, as opposed to corners (Figure
27 5E).
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 **Anti-nociceptive effect of encapsulated QX-314 involves TRPV1 receptors** 43

44 Because QX-314 acts on Na^+ channels from the intracellular side, it has to be
45 transported into nerve fibers once released inside the tissue. The key established
46 mechanism of this permeation involves transient receptor potential (TRP)-dependent
47 receptors TRPV1 (Binshtok *et al.*, 2007, Peters *et al.*, 2014) and TRPA1 (Roberson *et al.*
48 *et al.*, 2011, Brenneis *et al.*, 2014), although the Toll-like receptor 5 could also contribute
49 (Xu *et al.*, 2015). First, we confirmed that the injected microcapsules rest near the
50 peripheral nerve fibers (identified with neuron-specific PGP9.5 staining) innervating skin
51
52
53
54
55
56
57
58
59
60

1
2
3 tissue layers (Figure 6A). To determine whether the QX-314 action involves the TRP-
4 mediated pathway, we next used a model of neurogenic pain induced by capsaicin, a
5 prototypic TRPV1 agonist (Frias and Merighi, 2016).
6
7

8
9 Capsaicin (1.5 $\mu\text{g}/\mu\text{l}$) produced thermal hyperalgesia within a minute ($n = 6$ rats, $p <$
10 0.01), with an immediate adverse reaction of the animal (licking, shaking the injected
11 hind paw); the thermal hypersensitivity lasted up to 2–3 h, reversing back to control
12 values (Figure 6B). QX-314 (7.4 mM, non-capsulated) co-injected with capsaicin rapidly
13 produced anesthesia, which gradually developed into analgesia to a heat stimulus
14 within 3–5 h post-injection ($n = 6$ rats, $p < 0.05$ compared with capsaicin at the
15 corresponding time-points), fully consistent with previous observations (Binshtok *et al.*,
16 2007). The anti-nociceptive effect of QX-314 remained for several days ($n = 6$ rats, $p <$
17 0.05 compared with capsaicin at 1 to 5 days post-injection; Figure 6B). In contrast to the
18 complex cellular signaling mechanisms mediating the CFA-induced persistent
19 inflammatory pain, the capsaicin-induced neurogenic pain should specifically involve
20 TRPV1 activation at primary nociceptor afferents. Therefore, the most parsimonious
21 explanation of the prolonged analgesic effect observed in this study is that QX-314,
22 once injected subcutaneously, gets into the primary nociceptors through the activated
23 TRPV1 receptors and retained inside nerve fibers.
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 **Microcapsules undergo progressive biodegradation post-injection *in vivo***

39
40 The progressive and non-toxic biodegradation of the fabricated microcapsules is
41 important for their safe biomedical use. The capsules of a similar design and polymer
42 composition have already been validated for biodegradability and decomposition in
43 human cell lines (De Cock *et al.*, 2010, Pavlov *et al.*, 2011, Gao *et al.*, 2016). The
44 constituent nanomaterials have also been tested for their low-toxicity biodegradation *in*
45 *vivo* (Park *et al.*, 2009a, Chiappini *et al.*, 2015). To confirm the satisfactory
46 biodegradation of microcapsules used here, a *post-hoc* immunohistology was carried
47 out in tissue samples collected at different time-points after injecting microcapsules *in*
48 *vivo*.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 We assembled the integrated microcapsule fluorescence distributed in the z direction to
4 gauge the amount of fluorescently labelled capsules in the tissue volume (total scanned
5 volume of $\sim 370 \mu\text{m}^3$). Five weeks or later post-injection, this distribution was reduced
6 dramatically (Figure 6C; there was no detectable photo-bleaching of TRITC in individual
7 remaining capsules at these time-points). In parallel, we monitored the average
8 diameter of the remaining microcapsules (those with a distinguishable shape). As
9 biodegradation of the multiple layers comprising the capsule shell is expected to start
10 from the outer layer, it should gradually reduce the visible capsule size – this we
11 precisely observed ($p < 0.01$ or $p < 0.001$ compared with the initial time-point, 3 h post-
12 injection; Figure 6D) as a confirmation of robust enzymatic decomposition of the
13 microcapsule shell material within live tissue over a time post-injection.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

Improving the treatment of persistent pain is amongst the most challenging tasks in clinical practice today, directly affecting the lives of millions. Systemic administration of established painkillers over a prolonged period of time tends to have serious side effects and is therefore considered suboptimal. When the peripheral source of pain can be localized, the existing methods of local anesthesia rely either on a direct repetitive drug injection or on the permanent drug-administering devices. Both methods have serious limitations pertinent to the patient's discomfort, the costs involved, and a possible systemic escape of the drug.

The present study was prompted by the recent breakthroughs in the nano-engineering LbL technology, which enables micro-encapsulation and subsequent controllable release for the medicine of choice. A wide variety of substances have successfully been used as a payload for encapsulation (De Cock *et al.*, 2010). The capsule size could be adjusted between 0.3 μm and $>10 \mu\text{m}$ (determined by their template), whilst the surface functionality is provided by the outer layers. Crucially, the capsule shell permeability can be made sensitive to environmental variations (pH, temperature, osmolarity) (Delcea *et al.*, 2011) or a remote physical stimulus (light, magnetic field, ultrasound) (Antipina and Sukhorukov, 2011), which is achieved through the incorporation of sensitive elements into the multilayer capsule wall (Munoz Javier *et al.*, 2008, Pavlov *et al.*, 2011, Pavlov *et al.*, 2013, Gao *et al.*, 2016). The LbL microcapsules normally show no toxicity or appreciable inflammation effects (Pavlov *et al.*, 2011) and in most cases they are fabricated using standard biodegradable components (e.g., hyaluronic acid, dextran derivatives and other polysaccharides, gelatine and other peptides) approved by the FDA and equivalent European regulatory authorities for use in humans (Zhang *et al.*, 2013). They therefore generally meet the requirements for a safe drug delivery platform suitable for use in humans.

In parallel, there has been a growing interest in the Na^+ channel blocker QX-314, which appears to be more potent and longer-lasting in its analgesic effects in mammals, compared to the more traditional painkillers (Lim *et al.*, 2007, Roberson *et al.*, 2011, Zhao *et al.*, 2014). It is also routinely used in experimental neurophysiology research for

1
2
3 dampening neuronal excitability. Although QX-314 is a membrane-impermeable
4 compound which blocks Na⁺ channels from the cytoplasm side, studies *in situ* have
5 established that it enters nerve cells through the TRP receptors subtypes TRPV1 and
6 TRPA1 (Binshtok *et al.*, 2007, Leffler *et al.*, 2011, Stueber *et al.*, 2016) and possibly also
7 through a TRP-independent mechanism (Brenneis *et al.*, 2014, Hofmann *et al.*, 2014).
8
9

10
11
12 Our research strategy sought to combine these two recent lines of enquiry, aiming to
13 test it in a case study in rats whether encapsulated QX-314 could improve peripheral
14 pain treatment compared to more traditional approaches. This strategy achieved several
15 objectives. Firstly, we nano-engineered encapsulated QX-314, injected the
16 microcapsules into individual nerve cells (in culture) and documented gradual
17 suppression of excitability in individual neurons under whole-cell electrophysiological
18 control. Secondly, we evaluated and adjusted the microcapsule properties in the target
19 tissue areas *in situ* to ensure relatively slow, long-term local release of the encapsulated
20 cargo. Thirdly, and perhaps most importantly, we found that a single local injection of
21 encapsulated QX-314 had a robust anti-nociceptive effect in an animal model of
22 persistent inflammatory pain *in vivo*. The effect, which lasted for more than one week,
23 was documented using the semi-automated measurements of the pain threshold and
24 camera-traced quantification of the animal locomotion and explorative behavior. The
25 results were gauged against the groups of inflamed animals which received a single
26 injection of either empty microcapsules or non-encapsulated QX-314, and also the
27 control groups of non-inflamed animals or those with an injection of empty
28 microcapsules. Finally, we established that, consistent with the previous observations,
29 the prevalent cellular mechanism enabling intracellular QX-314 action is likely to involve
30 TRPV1 receptors and that the microcapsules undergo robust biodegradation from Week
31 5 post-injection onwards.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47
48 Clearly, although the LbL microcapsules are proving themselves as a highly flexible
49 method of drug encapsulation and delivery, the injection method described here
50 provides relatively limited control over their precise positioning, dosage, and spread in
51 the target tissue. Remote control of microcapsule movement inside tissue could further
52 improve to the coordinate precision of drug delivery. Another promising objective for the
53 future development is to equip the surface of microcapsules with physicochemical
54
55
56
57
58
59
60

1
2
3 properties that would help to recognize target tissue or cells. In terms of practical
4 application, further tests are needed to establish the stability and the storage
5 requirements for the microencapsulated medicine, including the costs involved.
6
7 Nonetheless, the present results suggest that LbL microcapsules represent a promising
8 approach to provide long-lasting, efficient and controllable focal delivery of anti-
9 nociceptive drugs, with limited side effects on the systemic level.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review Only

Acknowledgments

This work was supported by a Wellcome Trust Principal Fellowship (101896), European Research Council Advanced Grant (323113 NETSIGNAL), Russian Science Foundation grant (15-14-30000, computing cluster setup), FP7 ITN (606950 EXTRABRAIN), European Research Council Proof-of-Concept Grant (767372 NEUROCLOUD). The authors thank Prof Martin Koltzenburg and Dr Mona AlQatary for valuable comments and technical guidance.

Author Contributions

G.B.K., L.D., and A.S. designed and manufactured nano-engineered microcapsules; O.K., K.Z., and D.A.R. designed physiological and imaging experiments; O.K. and N.V. designed behavioral experiments; O.K. carried out physiological and behavioral studies; O.K. and K.Z. carried out imaging experiments; all authors contributed to data analysis and illustrations; O.K., G.B.K., and D.A.R. wrote the manuscript.

Disclosure statement

The authors report no conflict of interests.

REFERENCES

- Antipina MN & Sukhorukov GB. (2011). Remote control over guidance and release properties of composite polyelectrolyte based capsules. *Adv Drug Deliv Rev* 63:716-29.
- Binshtok AM, Bean BP & Woolf CJ. (2007). Inhibition of nociceptors by TRPV1-mediated entry of impermeant sodium channel blockers. *Nature* 449:607-10.
- Brenneis C, Kistner K, Puopolo M, et al. (2014). Bupivacaine-induced cellular entry of QX-314 and its contribution to differential nerve block. *Br J Pharmacol* 171:438-51.
- Chiappini C, De Rosa E, Martinez JO, et al. (2015). Biodegradable silicon nanoneedles delivering nucleic acids intracellularly induce localized in vivo neovascularization. *Nat Mater* 14:532-9.
- De Cock LJ, De Koker S, De Geest BG, et al. (2010). Polymeric multilayer capsules in drug delivery. *Angew Chem Int Ed Engl* 49:6954-73.
- Decher G. (1997). Fuzzy Nanoassemblies: Toward Layered Polymeric Multicomposites. *Science* 277:1232-1237.
- Delcea M, Mohwald H & Skirtach AG. (2011). Stimuli-responsive LbL capsules and nanoshells for drug delivery. *Adv Drug Deliv Rev* 63:730-47.
- Ermolyuk YS, Alder FG, Surges R, et al. (2013). Differential triggering of spontaneous glutamate release by P/Q-, N- and R-type Ca²⁺ channels. *Nat Neurosci* 16:1754-63.
- Frias B & Merighi A. (2016). Capsaicin, Nociception and Pain. *Molecules* 21.
- Gao H, Goriacheva OA, Tarakina NV, et al. (2016). Intracellularly Biodegradable Polyelectrolyte/Silica Composite Microcapsules as Carriers for Small Molecules. *ACS Appl Mater Interfaces* 8:9651-61.
- Hofmann ME, Largent-Milnes TM, Fawley JA, et al. (2014). External QX-314 inhibits evoked cranial primary afferent synaptic transmission independent of TRPV1. *J Neurophysiol* 112:2697-706.
- Hua S & Cabot PJ. (2013). Targeted nanoparticles that mimic immune cells in pain control inducing analgesic and anti-inflammatory actions: a potential novel treatment of acute and chronic pain condition. *Pain Physician* 16:E199-216.
- Kopach O, Krotov V, Belan P, et al. (2015). Inflammatory-induced changes in synaptic drive and postsynaptic AMPARs in lamina II dorsal horn neurons are cell-type specific. *Pain* 156:428-38.
- Kopach O, Krotov V, Goncharenko J, et al. (2016). Inhibition of Spinal Ca(2+)-Permeable AMPA Receptors with Dicationic Compounds Alleviates Persistent Inflammatory Pain without Adverse Effects. *Front Cell Neurosci* 10:50.
- Kopach O, Viatchenko-Karpinski V, Atianjoh FE, et al. (2013). PKC α is required for inflammation-induced trafficking of extrasynaptic AMPA receptors in tonically firing lamina II dorsal horn neurons during the maintenance of persistent inflammatory pain. *J Pain* 14:182-92.
- Kopach O, Viatchenko-Karpinski V, Belan P, et al. (2012). Development of inflammation-induced hyperalgesia and allodynia is associated with the upregulation of extrasynaptic AMPA receptors in tonically firing lamina II dorsal horn neurons. *Front Physiol* 3:391.

- 1
2
3 Leffler A, Lattrell A, Kronewald S, et al. (2011). Activation of TRPA1 by membrane
4 permeable local anesthetics. *Mol Pain* 7:62.
- 5 Lim TK, Macleod BA, Ries CR, et al. (2007). The quaternary lidocaine derivative, QX-
6 314, produces long-lasting local anesthesia in animal models in vivo.
7 *Anesthesiology* 107:305-11.
- 8 Liu Q, Zhan C, Barhoumi A, et al. (2016). A Supramolecular Shear-Thinning Anti-
9 Inflammatory Steroid Hydrogel. *Adv Mater* 28:6680-6.
- 10 Mishra A, Reynolds JP, Chen Y, et al. (2016). Astrocytes mediate neurovascular
11 signaling to capillary pericytes but not to arterioles. *Nature Neurosci* 19:1619-
12 1627.
- 13 Munoz Javier A, Del Pino P, Bedard MF, et al. (2008). Photoactivated release of cargo
14 from the cavity of polyelectrolyte capsules to the cytosol of cells. *Langmuir*
15 24:12517-20.
- 16 Park JH, Gu L, Von Maltzahn G, et al. (2009a). Biodegradable luminescent porous
17 silicon nanoparticles for in vivo applications. *Nat Mater* 8:331-6.
- 18 Park JS, Voitenko N, Petralia RS, et al. (2009b). Persistent inflammation induces GluR2
19 internalization via NMDA receptor-triggered PKC activation in dorsal horn
20 neurons. *J Neurosci* 29:3206-19.
- 21 Pavlov AM, De Geest BG, Louage B, et al. (2013). Magnetically engineered
22 microcapsules as intracellular anchors for remote control over cellular mobility.
23 *Adv Mater* 25:6945-50.
- 24 Pavlov AM, Sapelkin AV, Huang X, et al. (2011). Neuron cells uptake of polymeric
25 microcapsules and subsequent intracellular release. *Macromol Biosci* 11:848-54.
- 26 Peters CM, Ririe D, Houle TT, et al. (2014). Nociceptor-selective peripheral nerve block
27 induces delayed mechanical hypersensitivity and neurotoxicity in rats.
28 *Anesthesiology* 120:976-86.
- 29 Roberson DP, Binshtok AM, Blasi F, et al. (2011). Targeting of sodium channel blockers
30 into nociceptors to produce long-duration analgesia: a systematic study and
31 review. *Br J Pharmacol* 164:48-58.
- 32 Rwei AY, Lee JJ, Zhan C, et al. (2015). Repeatable and adjustable on-demand sciatic
33 nerve block with phototriggerable liposomes. *Proc Natl Acad Sci U S A*
34 112:15719-24.
- 35 Stuart MA, Huck WT, Genzer J, et al. (2010). Emerging applications of stimuli-
36 responsive polymer materials. *Nat Mater* 9:101-13.
- 37 Stueber T, Eberhardt MJ, Hadamitzky C, et al. (2016). Quaternary Lidocaine Derivative
38 QX-314 Activates and Permeates Human TRPV1 and TRPA1 to Produce
39 Inhibition of Sodium Channels and Cytotoxicity. *Anesthesiology* 124:1153-1165.
- 40 Sukhorukov GB & Mohwald H. (2007). Multifunctional cargo systems for biotechnology.
41 *Trends Biotechnol* 25:93-8.
- 42 Sukhorukov GB, Rogach AL, Zebli B, et al. (2005). Nanoengineered polymer capsules:
43 tools for detection, controlled delivery, and site-specific manipulation. *Small*
44 1:194-200.
- 45 Tanbour R, Martins AM, Pitt WG, et al. (2016). Drug Delivery Systems Based on
46 Polymeric Micelles and Ultrasound: A Review. *Curr Pharm Des* 22:2796-807.
- 47 Xu ZZ, Kim YH, Bang S, et al. (2015). Inhibition of mechanical allodynia in neuropathic
48 pain by TLR5-mediated A-fiber blockade. *Nat Med* 21:1326-31.
- 49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 Zhan C, Wang W, Mcalvin JB, et al. (2016). Phototriggered Local Anesthesia. *Nano Lett*
4 16:177-81.
5 Zhang Y, Chan HF & Leong KW. (2013). Advanced materials and processing for drug
6 delivery: the past and the future. *Adv Drug Deliv Rev* 65:104-20.
7 Zhao Y, Zhou C, Liu J, et al. (2014). The quaternary lidocaine derivative QX-314
8 produces long-lasting intravenous regional anesthesia in rats. *PLoS One*
9 9:e99704.
10
11 Zheng K, Bard L, Reynolds JP, et al. (2015). Time-resolved imaging reveals
12 heterogeneous landscapes of nanomolar Ca^{2+} in neurons and astroglia. *Neuron*
13 88:277–288.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review Only

FIGURE LEGENDS

Figure 1. Encapsulated QX-314 delivered intracellularly gradually suppresses neuronal excitability *in vitro*.

- (A) A snapshot showing the suspension of nano-engineered microcapsules (magnified on the right), with encapsulated Alexa Fluor 488; confocal imaging ($\lambda_x = 488$ nm).
- (B) Monitoring gradual release of encapsulated Alexa Fluor 488 from microcapsules; ordinate, time course of average capsule fluorescence normalized to the initial value; solid line, best-fit bi-exponential approximation (with 0.04 and 0.96 partial weights, respectively; decay constants as shown; $n = 1.6 \cdot 10^8$ microcapsules).
- (C) Snapshots displaying the patch pipette tip filled with microcapsules (TRITC fluorescence) prior to patching (left), when targeting a cultured neuron (middle), and in whole-cell configuration 25 min following intracellular delivery of microcapsules (right; DIC + fluorescence images of the same cell).
- (D) Traces, examples of current-clamp recordings of neuronal firing in control condition and after injection of encapsulated QX-314 (immediately after breaking-in and 20 min later, as indicated). Graph, statistical summary: time course of the maximal neuronal firing rate in control cells (no microcapsules; $n = 17$), with empty microcapsules injected ($n = 12$), encapsulated QX-314 injected ($n = 18$), with non-encapsulated QX-314 injected at 0.5 mM ($n = 6$) and 5 mM ($n = 4$), as indicated.
- (E) Left, examples of neuronal firing in response to a slow-ramp current after infusion of encapsulated QX-314 (left, 0 min and 20 min post injection in the same cell; dotted boxes indicate first spikes selected for comparisons); right, example of single action potential evoked in hippocampal neurons, with the estimated parameters indicated (FWHM, full width at half maximum).
- (F) Time course of the relative spike amplitude (left) and the spike overshoot (amplitude above 0 mV; right) in control condition (no capsules, black dots) and after intracellular delivery of encapsulated QX-314 (red dots), as indicated; spike sampling as shown in panel E (left); control, $n = 9$ neurons; encapsulated QX-314, $n = 9$ neurons.

All data are shown as mean \pm SEM. ** $p < 0.01$, *** $p < 0.001$ (unpaired t-test).

1
2
3
4
5
6
7 **Figure 2. Encapsulated QX-314 gradually increases cell input resistance of**
8 **neurons while reducing their firing rate in a dose-dependent manner.**
9

- 10 (A) Traces, examples of the membrane potential response (top) to current step pulses
11 (bottom) in the same neuron (control condition, no microcapsules) at two time
12 points, as indicated. Dashed lines, time window (stable response) where the input
13 resistance was estimated. Graph, examples of the current-voltage relationship at
14 three time points, as indicated, in control conditions.
15
16 (B) Examples of the current-voltage relationship at three time points, as indicated,
17 after the injection of empty microcapsules.
18
19 (C) Traces, examples of the membrane potential response (top) to a current injection
20 (bottom) at three time points after intracellular delivery of encapsulated QX-314, as
21 indicated. Graph, examples of the current-voltage relationship at three time points,
22 as indicated, for the same cell.
23
24 (D) Time course of the cell input resistance in control (n = 14 neurons), post-infusion
25 of empty microcapsules (n = 15) or encapsulated QX-314 (n = 14), as indicated.
26
27 (E) Traces, representative recordings of neuronal firing after whole-cell dialysis with
28 different concentrations of QX-314, at two time points, as indicated.
29
30 (F) Time course of the maximum cell firing rate for different concentrations of free QX-
31 314, compared with encapsulated QX-314, added to the intracellular medium, as
32 indicated.
33
34
35
36
37
38
39
40
41

42 Data are mean \pm SEM; * $p < 0.05$ (unpaired t-test).
43
44
45
46
47

48 **Figure 3. Long-lasting release of encapsulated cargo inside glabrous skin *in situ*.**

- 49 (A) Left image, acute skin tissue preparation from plantar surface of the rat hind paw
50 (DIC image) depicting region of interest (ROI, dotted rectangle). Right images, ROI
51 enlarged and shown in fluorescence channel ($\lambda_x^{2P} = 800$ nm), depicting injected
52 microcapsules (top, encapsulated Alexa Fluor 488), and the subsequently
53
54
55
56
57
58
59
60

1
2
3 positioned micropipette tip filled with free Alexa Fluor 488 (bottom); dotted line:
4 line-scan position.
5

- 6
7 **(B)** Concentration kinetics of encapsulated Alexa Fluor 488 release from
8 microcapsules *in situ* (mean \pm SEM, n = 10); red line, best fit bi-exponential
9 approximation (τ_1 , τ_2 - decay constants, 0.04 and 0.96 partial weights partial
10 weights, respectively).
11
12 **(C)** Image, example of line-scan (position in A, right bottom image; $\lambda_x^{2P} = 800$ nm)
13 depicting the escape of non-capsulated Alexa Fluor 488 injected from the
14 micropipette. Graph, concentration kinetics of free Alexa Fluor 488 injected from
15 the micropipette (0.75 s pressure pulse) *in situ*; red line, best fit bi-exponential
16 approximation (τ_1 , τ_2 - decay constants, 0.08 and 0.92 partial weights,
17 respectively).
18
19 **(D)** Image, experimental arrangement for photon-counting of spatial Alexa Fluor 488
20 fluorescence escape: a single microcapsule shown in 99% glycerol (arrow,
21 depiction of the radial profile calculation). Graph, radial profiles of Alexa Fluor 488
22 generated photon counts in two experimental conditions, as indicated (shaded
23 area: capsule radius).
24
25 **(E)** Image, example of a microcapsule in the epidermal-dermal area at different time-
26 points (0-7 h, as indicated) following injection into acute skin tissue *in situ* (arrow,
27 depiction of the radial profile calculation). Graph, radial profiles of Alexa Fluor 488
28 generated photon counts in the epidermal-dermal area, at different time points
29 after injection, as indicated (shaded area: capsule radius).
30
31
32
33
34
35
36
37
38
39
40
41
42

43 **Figure 4. The anti-nociceptive effect of encapsulated QX-314 in a persistent pain**
44 **model in rodents.**
45

- 46 **(A)** Image panels, examples of rat hind paw following injection of CFA with no
47 treatment (top row) and with encapsulated QX-314 (~3 mM; bottom row) at
48 different time points, as indicated; ipsi, ipsilateral, inflammatory side; contra:
49 contralateral, non-inflamed, side. Graph, time course of the thermal nociceptive
50 threshold in control (contralateral, n = 5 rats) and CFA-inflamed animals injected
51
52
53
54
55
56
57
58
59
60

with empty microcapsules (n = 5) or encapsulated QX-314 (~3 mM, n = 6) or non-encapsulated QX-314 (100 mM, n = 5), as indicated.

- (B) Time course of the thermal nociceptive threshold (normalized to that at the treatment onset, which is 24 hours post-CFA), for different dosage of encapsulated QX-314, as indicated: 10 μ M (n = 6 rats), 1 mM (n = 8), 3 mM (n = 6), and 7.5 mM (n = 7).
- (C) Fluorescent image (FITC fluorescence, transverse skin tissue section) displaying the epidermal-dermal area (the rat hind paw) with scattered microcapsules on Day 1 after microcapsule injection.
- (D) Time course of inflammatory hypersensitivity in rats with persistent peripheral inflammation following treatment with different amounts of QX-314 per capsule, as indicated (animals received the same overall dose of QX-314, 1 mM): 4.5 pg (n = 6 rats), 10 pg (n = 8), 0 pg (empty, n = 5).
- (E) Time course of inflammatory hypersensitivity with QX-314 in microcapsules of different sizes (animals received the same overall dose of encapsulated QX-314, 3 mM): 2 μ m diameter (n = 6 rats), 1 μ m (n = 9), empty (varied size, n = 5).
- Data are shown as mean \pm SEM. ** $p < 0.01$ (one-way ANOVA with Bonferroni post hoc test for encapsulated QX-314 compared with empty microcapsules).

Figure 5. Encapsulated QX-314 abolishes locomotive deficit and anxiety in animals with persistent peripheral inflammation.

- (A) Examples of the open-field test trajectory records taken from one animal at different time-points following CFA injection and treatment with encapsulated QX-314 (1 mM, 1 d post-CFA), as indicated; *D*, overall distance (meters) travelled over 10.0 min.
- (B) The effect of encapsulated QX-314 on animal locomotion: time course of the average exploration distance travelled by CFA-inflamed animals injected with encapsulated QX-314 (1 mM) or empty microcapsules, and by healthy animals (no CFA) injected with empty microcapsules.
- (C) The dose-effect of encapsulated QX-314 on exploratory activity in CFA-inflamed animals: time course of the average distance (normalized by that 1 d post-CFA)

1
2
3 travelled by CFA-inflamed rats; treatment with empty capsules (n = 5 rats), 10 μ M
4 encapsulated QX-314 (n = 5), 1 mM encapsulated QX-314 (n = 5), 3 mM
5 encapsulated QX-314 (n = 9), 10 mM encapsulated QX-314 (n = 6), as indicated.
6
7

- 8
9
10 (D) The effect of encapsulated QX-314 on the average speed that animals could
11 develop following treatment; notations as in B.
12
13 (E) The effect of encapsulated QX-314 on the animal's anxiety, estimated as the
14 average fraction (%) of time spent in the arena corners (correlative anxiety
15 indicator; left) *versus* the arena center (anti-correlative anxiety indicator; right).
16 Treatment with empty capsules (n = 5 rats), 10 μ M encapsulated QX-314 (n = 5), 1
17 mM encapsulated QX-314 (n = 5).
18
19

20 Data are shown as mean \pm SEM. * $p < 0.05$, ** $p < 0.01$ (one-way ANOVA with
21 Bonferroni post hoc test).
22
23
24
25

26 **Figure 6. Microcapsules co-localize with peripheral nerve fibers, engage TRPV1-**
27 **mediated analgesic effect of QX-314, and degrade with a time.**
28
29

- 30 (A) Examples of immunohistology of glabrous skin tissue (individual focal planes
31 shown) for microcapsules carrying encapsulated QX-314 (3 mM; TRITC
32 fluorescence, red) surrounding peripheral nerve fibers (neuron-specific PGP9.5
33 staining, green). Transverse skin sections (30 μ m thick).
34
35
36
37 (B) Time course of the thermal pain threshold in animals injected with capsaicin (1.5
38 μ g μ l⁻¹, n = 6 rats) or with capsaicin together with 7.4 mM QX-314 (non-capsulated,
39 n = 6). Data are mean \pm SEM. * $p < 0.05$, ** $p < 0.01$ (one-way ANOVA with
40 Bonferroni post hoc test).
41
42
43
44 (C) The z-axis profile of the microcapsule fluorescence (TRITC, $\lambda_x^{2P} = 820$ nm; 3 mM
45 encapsulated QX-314, integrated fluorescence) inside the skin tissue from the rat
46 hind paw at different times post-injection *in vivo*, as indicated. Total scanned
47 volume ~ 370 μ m³; 3 μ m z-steps.
48
49
50
51 (D) Averaged diameter of microcapsules inside the skin tissue from the rat hind paw at
52 different time points post-injection *in vivo*, as indicated. The reduced diameter
53 reflects progressive degradation of the outer capsule shell. Total number of
54
55
56
57
58
59
60

1
2
3 analyzed capsules is indicated; ** $p < 0.01$, *** $p < 0.001$ (one-way ANOVA with
4 Fisher test).
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review Only




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5





Figure 6

1
2 **Nano-engineered microcapsules boost the treatment of persistent**
3
4 **pain**
5
6
7


8 **Additional Figures**
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review Only

(A)



(B)



Additional Figure 1. Persistent inflammatory pain remains refractory to single focal injection of lidocaine.


(A) Time course of the thermal nociceptive threshold (Hargreaves test) for the CFA-inflamed animals. Empty microcapsules (no payload) produced no changes in the CFA-induced peripheral thermal hypersensitivity in rats after injection into inflamed tissue, as indicated. Number of animals tested: $n = 27$ with CFA-induced peripheral inflammation, no capsules, and $n = 6$ CFA-inflamed rats injected with empty microcapsules.

1
2 **(B)** Time course of the thermal nociceptive threshold in CFA-inflamed animals with
3 no treatment or injected with 2%, as indicated; n = 15 rats for CFA group, n =
4 5 CFA-inflamed rats treated with lidocaine.
5
6


7 Data are shown as mean \pm SEM.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review Only

(A)




(B)




Additional Figure 2. Testing the concomitant effects of microcapsules *in vivo*.

In non-inflamed animals, empty microcapsules (no payload, **A**) or encapsulated QX-314 (**B**) had no effect on the time course of the thermal threshold of the ipsilateral hind paw compared to naïve animals (no microcapsules injected). Number of animals tested: $n = 5$ rats for empty microcapsules, $n = 6$ animals for encapsulated QX-314. Data are mean \pm SEM.

(A)



(B)



Additional Figure 3. Encapsulated QX-314 improves impaired locomotion in animals with persistent peripheral inflammation.

(A) The dose-dependent effect of encapsulated QX-314 on the average acceleration that animals with inflamed hind paw display in an open-field test following treatment, as indicated. Number of animals tested: $n = 5$ rats for

1
2 empty microcapsules, n = 4 animals for 1 mM encapsulated QX-314; n = 5
3
4 animals for 10 μ M encapsulated encapsulated QX-314.

- 5
6 **(B)** Time course of the average acceleration that animals with the CFA-inflamed
7 hind paw display in an open-field test following lidocaine treatment (a single
8 injection of 2% lidocaine) or injection of empty microcapsules, as indicated.
9
10 Number of animals tested: n = 6 treated with lidocaine, n = 5 injected with
11
12 empty microcapsules.
13

14 Data are shown as mean \pm SEM. * $p < 0.05$ (one-way ANOVA with Bonferroni post
15
16 hoc test).
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60